Wednesday, 24 April 2024

Announcement

TAKEOVER: ABA: ABA Appoints Independent Adviser

14 Nov 2016 09:37NZX
ABANO APPOINTS INDEPENDENT ADVISER AND RECOMMENDS SHAREHOLDERS TAKE NO ACTION

Abano Healthcare Group Limited (NZX:ABA) has appointed Grant Samuel &
Associates Limited  to prepare the Independent Adviser''s Report required
under the Takeovers Code, on the merits of the proposed partial takeover
offer from Healthcare Partners Holdings Limited (Healthcare Partners).

Healthcare Partners is a company associated with Peter and Anya Hutson and
James Reeves. These individuals have all been involved in previous attempts
to gain control of Abano and to force changes to Abano''s Board to advance
their own objectives. These prior attempts have been unsuccessful and
disruptive to Abano, and have cost Abano shareholders in excess of $1
million, not including management time.

Shareholders should take no action until they receive the Target Company
Statement

The Abano Board recommends that shareholders take no action in respect of,
and do not enter into any commitment to accept, the proposed offer.
Shareholders should wait until they receive the Target Company Statement,
which will include the Board''s formal recommendation and the Independent
Adviser''s Report, before deciding to accept or reject the offer.

Abano Board''s preliminary view on Healthcare Partners'' proposed partial offer

The Abano Board''s preliminary view is that the partial nature of this offer
is not in the best interests of all shareholders and does not reflect full
and fair value for the control that would be attained by Peter and Anya
Hutson and James Reeves, or appropriate compensation for all of the risks
associated with remaining a minority shareholder in the company.

The Abano Board wishes to ensure that shareholders clearly understand the
nature of a partial offer. It is not an offer for all shares. The indicated
offer price of $10.00 is only available on those shares accepted under the
offer. Acceptances from shareholders will be scaled down if the total
acceptances received exceed the number of shares required to take Healthcare
Partners from its current 19.02% holding to 50.01% of Abano. If all
shareholders offered all of their shares, this would result in as little as
38% of each shareholding being accepted under the offer. In addition, the
premium offered will only be available on shares that are taken up under the
offer. This must be considered in light of the potential reduction in value
for the retained shares not sold through the offer.

The Board believes that the premium for a partial takeover offer of this
nature must compensate shareholders for:

1. Passing control to a majority shareholder where shareholders are highly
unlikely to be able to sell all of their shares into the offer;

2. Receiving a premium for that control on only a portion of their shares (in
this case, potentially only 38% of shares held), and where it would be most
unusual to have a premium for control paid for the balance of the shares in
the future;

3. The risk of reduced liquidity (the ability for shareholders to sell their
shares) and the probability of a decline in market price on their retained
Abano shares after the offer; and

4. The potential impact on the value of Abano shares post-takeover, as a
result of the significant reversal in Abano''s growth strategy which is being
proposed in the draft offer.

Abano is a valuable business delivering long term shareholder value

Since Mr Hutson''s last attempt to gain control of Abano in August 2013, the
share price has risen 41% (footnote 1).  Shareholders have received a Total
Shareholder Return of 13.9% p.a. on their investment in Abano during this
period, outperforming the market and above the NZX ALL return of 13.3% p.a
and the NZX 50 return of 12.9% p.a. for the same period (footnote 2).

Oversight of Abano''s growth strategy is provided by an experienced and
capable Board. This is evidenced by the performance of the company, as the
results and financial returns demonstrate, and by external recognition from
industry peers. Trevor Janes, Abano''s Chairman, has recently been announced
as a finalist for Chairperson of the Year in the 2016 Deloitte Top 200
Awards. In addition, both Trevor and Abano director Ted van Arkel, sit on the
boards of companies that have also been named as Award finalists in the
excellence in governance and company of the year categories, demonstrating
the calibre of Abano''s Board.

Appointment of other advisers

The Abano Board has appointed specialist legal advisory firm, Harmos Horton
Lusk, and Forsyth Barr as financial adviser, to assist the Board in
evaluating and responding to the proposed offer. The Directors'' formal
recommendation, along with the Independent Adviser''s Report, will be included
in the Target Company Statement, which will be sent to shareholders.

ENDS

1. Abano share price: 30 day VWAP including 6 August 2013 (the day prior to
announcement of unsolicited indicative proposal) of $5.85, and $8.27, being
the 30 day VWAP including 3 November 2016 prior to receiving the initial
takeover notice.
2. NZX All and NZX 50 gross indices
End CA:00292570 For:ABA    Type:TAKEOVER   Time:2016-11-14 09:37:43
Views: 211
Abano Healthcare Group
 9.600 Change:
0.10
1.03%
 
Open:9.700 
High:9.700 
Low:9.700 
Volume:3,821 
Last Traded:07/02/18 09:10:26 
Bid:9.700 
Ask:9.600 
52-Wk High:10.500 
52-Wk Low:8.400